BeiGene
BGNE
#948
Rank
ยฃ16.26 B
Marketcap
ยฃ148.69
Share price
0.49%
Change (1 day)
7.34%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

EPS for BeiGene (BGNE)

EPS in 2023 (TTM): -ยฃ13.93

According to BeiGene 's latest financial reports the company's current EPS (TTM) is -ยฃ13.40. In 2022 the company made an earnings per share (EPS) of -ยฃ15.59 a decrease over its 2021 EPS that were of -ยฃ12.24.

EPS history for BeiGene from 2015 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-ยฃ13.93-10.65%
2022-ยฃ15.5927.35%
2021-ยฃ12.24-19.96%
2020-ยฃ15.3020.81%
2019-ยฃ12.6631.52%
2018-ยฃ9.63417.57%
2017-ยฃ1.86-37.16%
2016-ยฃ2.96158.95%
2015-ยฃ1.14

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-ยฃ0.80-93.99%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ0.22-98.38%๐Ÿ‡บ๐Ÿ‡ธ USA